The Role of PCSK9 Inhibitors in Lowering LDL-C and Reducing Cardiovascular Risk in Patients with Dyslipidemia
This CME program will feature content presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. Four expert faculty will analyze recent therapeutic advances in the treatment and management of patients with dylispidemia, as well as the role of PCSK9 inhibitors in lowering LDL-C and reducing cardiovascular risk in those patients. Long-term cardiovascular efficacy and safety data will be reviewed, and clinical relevance debated. Further, the expert faculty will outline strategies for utilizing the inter-professional team and incorporating recent data into individualized treatment plans. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of dyslipidemia as it relates to improving outcomes and quality of life in clinical practice.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with dyslipidemia.
Upon completion of this activity, participants will be better able to do the following:
- Review the role of PCSK9 inhibitors in lowering LDL-C in high cardiovascular risk patient populations
- Examine long-term cardiovascular efficacy and safety data of PCSK9 inhibitors for the treatment of dyslipidemia presented at ESC 2017
- Incorporate recent data into individualized treatment plans to reduce cardiovascular risk and improve outcomes for patients with dyslipidemia
Christopher P. Cannon, MD
Marc P. Bonaca, MD
Robert P. Giugliano, MD
Paul Ridker, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Christopher P. Cannon, MD|
Consultant/Advisor: Alnylam Pharmaceuticals, Inc; Amarin Pharma Inc.; Amgen Inc.; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; GlaxoSmithKline; KOWA Pharmaceuticals America, Inc.; LipimetiX Development Inc.; Merck & Co., Inc.; Pfizer Inc.; Regeneron; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support: Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Marc P. Bonaca, MD
Consultant/Advisor: Aralez Pharmaceuticals Inc.; AstraZeneca; Bayer Corporation; Merck & Co., Inc.
Grant/Research Support: AstraZeneca; MedImmune; Merck & Co., Inc.
Robert P. Giugliano, MD
Consultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company, Limited; GlaxoSmithKline; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; St. Jude Children's Research Hospital; Stealth Peptides Incorporated
Grant/Research Support: Amgen Inc.
Speaker's Bureau: Amgen Inc.; Daiichi Sankyo Company, Limited; Merck & Co., Inc.
Paul Ridker, MD
Consultant/Advisor: AstraZeneca; Sanofi; Teva Pharmaceutical Industries Ltd; QuintilesIMS
Grant/Research Support: AstraZeneca; KOWA Pharmaceuticals America, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Amgen Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
Credit Designation Statement
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician